Clinical Trials Logo

Advanced Solid Tumours clinical trials

View clinical trials related to Advanced Solid Tumours.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05920408 Terminated - Clinical trials for Advanced Solid Tumours

Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Start date: April 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1B/2A study to assess the safety, tolerability, pharmacokinetic and anti-tumoral activity of EXS21546 in combination with a PD-1 inhibitor in patients with advanced solid tumours.

NCT ID: NCT04959266 Terminated - Clinical trials for Advanced Solid Tumours

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Start date: June 28, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.

NCT ID: NCT04949425 Terminated - Clinical trials for Advanced Solid Tumours

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to allow continued adavosertib treatment of patients with advanced solid tumours participating in the adavosertib clinical pharmacology studies and to assess the continued safety and tolerability of adavosertib for patients enrolled in adavosertib clinical pharmacology studies (hereafter referred to as the 'parent studies') who continue to use the therapy

NCT ID: NCT01859351 Terminated - Clinical trials for Advanced Solid Tumours

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Start date: July 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.

NCT ID: NCT01668550 Terminated - Clinical trials for Advanced Solid Tumours

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours

AZD0424
Start date: October 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours

NCT ID: NCT01581060 Terminated - Clinical trials for Advanced Solid Tumours

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of part 1 of this study is to determine the optimal biological dose (OBD) and maximum tolerated dose (MTD) for WX-554 and the recommended dose/dose schedules for the chronic treatment in part 2. The aim of part 2 is to further determine the safety and tolerability of chronic treatment with WX-554.

NCT ID: NCT01252095 Terminated - Clinical trials for Advanced Solid Tumours

Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This first-in-human study aims to establish the maximum tolerated dose of PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.